Published in Nature on September 27, 1974
Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect Immun (1982) 3.02
Role for cell-mediated immunity in the resistance of mice to subcutaneous herpes simplex virus infection. Infect Immun (1975) 2.44
Natural killing of herpes simplex virus type 1-infected target cells: normal human responses and influence of antiviral antibody. Infect Immun (1979) 1.94
Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 1 infection. Infect Immun (1982) 1.92
Human polymorphonuclear leucocytes as mediators of antibody-dependent cellular cytotoxicity to herpes simplex virus-infected cells. Clin Exp Immunol (1977) 1.73
Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J Virol (1991) 1.73
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods (2010) 1.71
Antibody-mediated recovery from subcutaneous herpes simplex virus type 2 infection. Infect Immun (1978) 1.59
Role of antibody in primary and recurrent herpes simplex virus infection. J Virol (1985) 1.41
Human antibody-dependent cellular cytotoxicity. Isolation and identification of a subpopulation of peripheral blood lymphocytes which kill antibody-coated autologous target cells. J Clin Invest (1975) 1.40
Mechanisms of resistant of herpesviruses: comparison of the effectiveness of different cell types in mediating antibody-dependent cell-mediated cytotoxicity. Infect Immun (1977) 1.34
Mechanisms of recovery from Herpesvirus infections -a review. Can J Comp Med (1978) 1.34
Lysis of herpesvirus-infected cells by immune spleen cells. Infect Immun (1975) 1.32
Lymphocyte reactivity contributes to protection conferred by specific antibody passively transferred to herpes simplex virus-infected mice. Infect Immun (1980) 1.32
Passive immunization in experimental Herpesvirus hominis infection of newborn mice. Infect Immun (1975) 1.31
Immune interferon production by lymphoid cells: role in the inhibition of herpesviruses. Infect Immun (1976) 1.29
Role of Fc fragments in antibody-mediated recovery from ocular and subcutaneous herpes simplex virus infections. Infect Immun (1981) 1.21
Human antibody-dependent cell-mediated cytotoxicity against target cells infected with respiratory syncytial virus. Clin Exp Immunol (1977) 1.18
The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev (2014) 1.16
Antibody-dependent cellular cytotoxicity of Coxiella burnetii-infected J774 macrophage target cells. Infect Immun (1984) 1.11
Cell-mediated cytotoxicity to herpes-infected cells in humans: dependence on antibodies. Infect Immun (1977) 1.11
Evaluation of solubilized herpes simplex virus membrane antigen by enzyme-linked immunosorbent assay. J Clin Microbiol (1983) 1.04
Antibody-dependent cellular protection against herpes simplex virus dissemination as revealed by viral plauqe and infectivity assays. Infect Immun (1977) 1.03
A possible role for polymorphonuclear leucocytes in the defence against recrudescent herpes simplex virus infection in man. Immunology (1978) 1.01
Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology (2011) 0.97
Inactivation of varicella zoster virus in vitro: effect of leukocytes and specific antibody. Infect Immun (1981) 0.97
Human antibody-dependent cellular cytotoxicity and natural killer cytotoxicity to herpes simplex virus-infected autologous and allogeneic cells. Immunology (1983) 0.96
Monoclonal antibodies suppress replication of herpes simplex virus type 1 in trigeminal ganglia. J Virol (1984) 0.95
Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells. J Immunol (2013) 0.93
Augmentation of lymphocyte cytotoxicity by antibody to herpesvirus saimiri associated antigens. Proc Natl Acad Sci U S A (1975) 0.89
Presence of parasite antigen on the surface of P388D1 cells infected with Ehrlichia risticii. Infect Immun (1992) 0.87
Enhancement of antibody-dependent cell-mediated cytotoxicity of herpesvirus-infected cells by complement. Infect Immun (1977) 0.87
Cell cytotoxicity due to specific influenza antibody production in vitro after recent influenza antigen stimulation. Proc Natl Acad Sci U S A (1979) 0.83
Effect of herpes simplex virus infection on murine antibody-dependent cellular cytotoxicity and natural killer cytotoxicity. Infect Immun (1981) 0.80
Activity of rabbit monocytes, macrophages, and neutrophils in antibody-dependent cellular cytotoxicity of herpes simplex virus-infected corneal cells. Infect Immun (1982) 0.79
Analysis of the lytic step in the herpes simplex virus antibody-dependent cellular cytotoxicity system. Infect Immun (1980) 0.78
Role of antiviral antibodies in resistance against coxsackievirus B3 infection: interaction between preexisting antibodies and an interferon inducer. Infect Immun (1982) 0.78
Analysis of the adhesion step in the herpes simplex virus antibody-dependent cellular cytotoxicity system. Infect Immun (1979) 0.77
Adenine arabinoside (ARA-A) blocked HSV-2 infected human skin fibroblasts as targets for the detection of serum mediated and cellular cytotoxicity in patients with cervical carcinoma. Clin Exp Immunol (1976) 0.75
Reversal of antibody-dependent cellular cytotoxicity suppression by cycloheximide. Immunology (1985) 0.75
Functions of Antibodies. Microbiol Spectr (2014) 0.75
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Semin Immunol (2017) 0.75
Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med (1997) 7.59
Ampicillin-resistant Haemophilus influenzae type B infection. JAMA (1974) 5.90
Association of antigenic type of Herpesvirus hominis with site of viral recovery. J Immunol (1967) 5.07
Immunological aspects of demyelinating diseases. Annu Rev Immunol (1992) 4.39
Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med (1986) 4.37
Micromethod system for identification of anaerobic bacteria. Appl Microbiol (1973) 4.18
Infection with herpes-simplex viruses 1 and 2. 3. N Engl J Med (1973) 3.89
Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA (1988) 3.89
An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature (1998) 3.69
A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med (1982) 3.66
The natural history of herpes simplex virus infection of mother and newborn. Pediatrics (1980) 3.65
Prevalence of psychiatric disorders in youths across five sectors of care. J Am Acad Child Adolesc Psychiatry (2001) 3.59
Comparative study of diagnostic procedures for congenital cytomegalovirus infection. Pediatrics (1980) 3.53
Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature (1990) 3.50
Prevalence of adolescent substance use disorders across five sectors of care. J Am Acad Child Adolesc Psychiatry (2001) 3.39
Antigenic and biologic differences in herpesvirus hominis. Prog Med Virol (1968) 3.31
Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J Immunol (1981) 3.15
A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med (1989) 2.94
Herpesviridae. Definition, provisional nomenclature, and taxonomy. The Herpesvirus Study Group, the International Committee on Taxonomy of Viruses. Intervirology (1981) 2.92
Infection with herpes-simplex viruses 1 and 2. 1. N Engl J Med (1973) 2.87
Antibodies to Herpesvirus hominis types 1 and 2 in humans. I. Patients with genital herpetic infections. Am J Epidemiol (1970) 2.83
Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med (1994) 2.82
Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol (1991) 2.80
Immunity to influenza in ferrets. I. Response to live and killed virus. Br J Exp Pathol (1972) 2.78
Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med (1992) 2.71
Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics (1980) 2.70
Herpes simplex virus encephalitis: laboratory evaluations and their diagnostic significance. J Infect Dis (1982) 2.70
Varicella vaccine for healthy children. Lancet (1994) 2.64
Typing of Herpesvirus hominis strains by a direct immunofluorescent technique. Proc Soc Exp Biol Med (1969) 2.64
Infection of the newborn with herpesvirus hominis. Adv Pediatr (1970) 2.61
Detection of herpes simplex virus type 2-specific antibody with glycoprotein G. J Clin Microbiol (1985) 2.54
Cytology and histopathology of cervical herpes simplex infection. Cancer (1966) 2.52
Different patterns of neurologic involvement with herpes simplex virus types 1 and 2: isolation of herpes simplex virus type 2 from the buffy coat of two adults with meningitis. J Infect Dis (1973) 2.52
Ataxia-telangiectasia. Medicine (Baltimore) (1972) 2.50
Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus. J Immunol (1976) 2.49
Comparison of three anaerobic systems for the isolation of anaerobic bacteria from clinical specimens. Am J Clin Pathol (1973) 2.47
Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med (1991) 2.42
Perinatal risk associated with maternal genital herpes simplex virus infection. Am J Obstet Gynecol (1971) 2.40
Genital infection with type 2 Herpes virus hominis. A commonly occurring venereal disease. Br J Vener Dis (1969) 2.40
Relation of pock size on chorioallantoic membrane to antigenic type of herpesvirus hominis. Proc Soc Exp Biol Med (1968) 2.34
Isolation of an HTLV-1-like retrovirus from patients with tropical spastic paraparesis. Nature (1988) 2.27
Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J Infect Dis (1992) 2.25
Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation. Proc Natl Acad Sci U S A (1998) 2.22
Human monocyte-macrophage-mediated antibody-dependent cytotoxicity to herpes simplex virus-infected cells. J Immunol (1977) 2.21
Antibodies to Herpesvirus hominis types 1 and 2 in humans. II. Women with cervical cancer. Am J Epidemiol (1970) 2.15
A community surveillance system of infectious diseases in the greater Atlanta area. Am J Public Health Nations Health (1966) 2.11
Inhibitory effect of heparin on herpes simplex virus. J Bacteriol (1964) 2.11
Genital herpetic infection. Association with cervical dysplasia and carcinoma. Cancer (1969) 2.10
Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol (1990) 2.07
Further studies on the specificity of presumed immune associations of myasthenia gravis and consideration of possible pathogenic implications. Ann N Y Acad Sci (1966) 2.02
Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol (1991) 2.00
Genital herpes simplex infection. Virologic and cytologic studies. Obstet Gynecol (1967) 1.95
Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature (1984) 1.95
Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. Am J Pathol (2001) 1.94
Gestational, pathologic and biochemical differences between very long-chain acyl-CoA dehydrogenase deficiency and long-chain acyl-CoA dehydrogenase deficiency in the mouse. Hum Mol Genet (2001) 1.93
Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis (1995) 1.92
Effect of physician recommendation and patient adherence on rates of colorectal cancer testing. Cancer Detect Prev (2004) 1.90
Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis (1989) 1.89
Skewed T-cell receptor repertoire in genetically identical twins correlates with multiple sclerosis. Nature (1993) 1.89
Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab Invest (1981) 1.84
A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J Exp Med (1991) 1.84
Demonstration of exogenous genital reinfection with herpes simplex virus type 2 by restriction endonuclease fingerprinting of viral DNA. J Infect Dis (1979) 1.82
Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet (1984) 1.81
Quantitative analysis of genomic polymorphism of herpes simplex virus type 1 strains from six countries: studies of molecular evolution and molecular epidemiology of the virus. J Gen Virol (1994) 1.79
Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol (1995) 1.76
Changing presentation of herpes simplex virus infection in neonates. J Infect Dis (1988) 1.76
Transcriptional control of a nuclear gene encoding a mitochondrial fatty acid oxidation enzyme in transgenic mice: role for nuclear receptors in cardiac and brown adipose expression. Mol Cell Biol (1996) 1.73
Human polymorphonuclear leucocytes as mediators of antibody-dependent cellular cytotoxicity to herpes simplex virus-infected cells. Clin Exp Immunol (1977) 1.73
Multiple sclerosis (first of two parts). N Engl J Med (1982) 1.72
Immunity to influenza in ferrets. II. Influence of adjuvants on immunization. Br J Exp Pathol (1972) 1.70
A cross-sectional study of herpes simplex virus types 1 and 2 in college students: occurrence and determinants of infection. J Infect Dis (1990) 1.70
Role of T lymphocytes in recovery from murine cytomegalovirus infection. Infect Immun (1977) 1.68
Antigens of Herpes simplex virus type 1 and 2-immunodiffusion and inhibition passive hemagglutination studies. Z Immunitatsforsch Exp Klin Immunol (1971) 1.67
Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis (1996) 1.66
Infection with herpes-simplex viruses 1 and 2. II. N Engl J Med (1973) 1.64
Type-specific surface antigens of cells infected with herpes simplex virus (1 and 2). Proc Soc Exp Biol Med (1971) 1.64
Early progression of disease in HIV-infected infants with thymus dysfunction. N Engl J Med (1996) 1.63
Requirement for HLA-DR+ accessory cells in natural killing of cytomegalovirus-infected fibroblasts. J Exp Med (1986) 1.63
Experimental allergic encephalomyelitis: enhancement of cell-mediated transfer by concanavalin A. J Immunol (1977) 1.58
Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol (1993) 1.58
Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine (1991) 1.57
The structure of herpes simplex virus DNA and its application to molecular epidemiology. Ann N Y Acad Sci (1980) 1.52
The epidemiology of Type 2 (genital) herpes simplex virus infection. Obstet Gynecol Surv (1972) 1.52
Acute experimental allergic encephalomyelitis in the mouse: immunopathology of the developing lesion. Cell Immunol (1985) 1.52
Impaired lymphocyte transformation in ataxia-telangiectasia in part due to a plasma inhibitory factor. J Immunol (1969) 1.51
Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol (1992) 1.50
Filamentous structures of type 2 Herpesvirus hominis infection of the chorioallantoic membrane. J Virol (1969) 1.50
Abnormal nonshivering thermogenesis in mice with inherited defects of fatty acid oxidation. J Clin Invest (1998) 1.50
Effect of combinations of acyclovir with vidarabine or its 5'-monophosphate on herpes simplex viruses in cell culture and in mice. Antimicrob Agents Chemother (1982) 1.48
Detection by indirect immunofluorescence of Fc receptors in cells acutely infected with Herpes simplex virus. Int Arch Allergy Appl Immunol (1977) 1.46
The mononuclear cell in human blood which mediates antibody-dependent cellular cytotoxicity to virus-infected target cells. I. Identification of the population of effector cells. J Immunol (1977) 1.46